Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
The goal of this clinical trial is to learn if the SARS-CoV-2 subunit mucosal vaccine with the recombinant flagellin protein adjuvant works to Prevent COVID-19 infection. It will also learn about the Safety and immunogenicity of the vaccine.
Epistemonikos ID: 93b1c30096e5ed0c9f9d18850c96aa3bae85c463
First added on: Mar 27, 2025